Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BTAI logo BTAI
Upturn stock ratingUpturn stock rating
BTAI logo

BioXcel Therapeutics Inc (BTAI)

Upturn stock ratingUpturn stock rating
$2.57
Last Close (24-hour delay)
Profit since last BUY-62.21%
upturn advisory
WEAK BUY
BUY since 36 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/01/2025: BTAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $19.8

1 Year Target Price $19.8

Analysts Price Target For last 52 week
$19.8 Target price
52w Low $1.17
Current$2.57
52w High $13.28

Analysis of Past Performance

Type Stock
Historic Profit -93.26%
Avg. Invested days 18
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/01/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 53.05M USD
Price to earnings Ratio -
1Y Target Price 19.8
Price to earnings Ratio -
1Y Target Price 19.8
Volume (30-day avg) 3
Beta 0.21
52 Weeks Range 1.17 - 13.28
Updated Date 09/29/2025
52 Weeks Range 1.17 - 13.28
Updated Date 09/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.55

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -13210%

Management Effectiveness

Return on Assets (TTM) -68.72%
Return on Equity (TTM) -1766.94%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 144552362
Price to Sales(TTM) 59.71
Enterprise Value 144552362
Price to Sales(TTM) 59.71
Enterprise Value to Revenue 166.53
Enterprise Value to EBITDA -0.75
Shares Outstanding 19646801
Shares Floating 14151192
Shares Outstanding 19646801
Shares Floating 14151192
Percent Insiders 2.81
Percent Institutions 4.61

ai summary icon Upturn AI SWOT

BioXcel Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

BioXcel Therapeutics, Inc. was founded in 2010. It is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company's focus has evolved from broader applications of AI to a targeted approach in specific therapeutic areas, particularly mental health.

business area logo Core Business Areas

  • Neuroscience: Focuses on developing therapies for acute agitation and other neuropsychiatric disorders. The lead product is BXCL501 (dexmedetomidine sublingual film).
  • Immuno-oncology: This segment has been de-emphasized; however, previous research efforts aimed to leverage AI to identify novel immuno-oncology targets and develop related therapies.

leadership logo Leadership and Structure

The company is led by a management team with experience in pharmaceuticals and biotechnology. Key figures include the CEO and Chief Medical Officer. The organizational structure includes research and development, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • BXCL501 (Igalmi): A sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Market share data is still emerging. Competitors include traditional antipsychotics and benzodiazepines used off-label for agitation. The revenue for 2023 was approximately 7.3 Million US Dollars.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically within neuroscience, is characterized by high unmet needs and significant market opportunities. The market for treatments for agitation and other neuropsychiatric conditions is substantial.

Positioning

BioXcel Therapeutics is positioned as an innovator leveraging AI to identify and develop novel therapies in neuroscience. Their competitive advantage lies in the novel formulation and administration of dexmedetomidine for acute agitation.

Total Addressable Market (TAM)

The TAM for acute agitation treatment is estimated to be in the billions of dollars annually. BioXcel is positioned to capture a portion of this market with Igalmi, targeting a specific segment of patients experiencing agitation related to schizophrenia or bipolar disorder.

Upturn SWOT Analysis

Strengths

  • FDA-approved product (Igalmi)
  • Novel drug delivery system (sublingual film)
  • AI-driven drug discovery platform
  • Targeted approach to specific neuropsychiatric conditions

Weaknesses

  • Limited commercial infrastructure
  • Dependence on a single approved product
  • Relatively small company size compared to competitors
  • Past restructurings and pipeline refocusing can affect reputation

Opportunities

  • Expansion of Igalmi label to other indications (e.g., agitation in dementia)
  • Partnerships with larger pharmaceutical companies for commercialization
  • Development of new therapies using the AI platform
  • Growing awareness and acceptance of sublingual drug delivery

Threats

  • Competition from existing treatments and new entrants
  • Regulatory hurdles and potential setbacks in clinical trials
  • Pricing and reimbursement pressures
  • Potential safety concerns or adverse events associated with Igalmi

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • ABBV
  • TEVA
  • MYL

Competitive Landscape

BioXcel has a novel product in Igalmi but faces competition from established pharmaceutical companies with broader portfolios and resources. The AI platform is a potential differentiator.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by research and development progress and the approval of Igalmi.

Future Projections: Future growth is dependent on the successful commercialization of Igalmi and the development of new therapies. Analyst estimates vary, but generally project revenue growth in the coming years.

Recent Initiatives: Recent initiatives include focusing on commercializing Igalmi, cost-cutting measures, and rationalizing the pipeline.

Summary

BioXcel Therapeutics shows promise with Igalmi's approval and novel AI platform but faces financial constraints and significant competition. The company's growth depends on successful commercialization and pipeline expansion. It must manage its cash flow and navigate the regulatory landscape carefully, while the competition is strong with competitors such as LLY and ABBV. With future initiative the company has a large opportunity but the current financials make it a risky investment.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Press releases
  • Company Website

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BioXcel Therapeutics Inc

Exchange NASDAQ
Headquaters New Haven, CT, United States
IPO Launch date 2018-03-08
Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 37
Full time employees 37

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.